Skip to content

NeoGenomics NEO Common Stock, Shares, Outstanding

Common Stock, Shares, Outstanding at other companies

Labcorp Holdings logo
Labcorp HoldingsLH
Guardant Health logo
Guardant HealthGH
Natera, Inc. logo
Natera, Inc.NTRA
GeneDx Holdings logo
GeneDx HoldingsWGS
Agilent Technologies logo
Agilent TechnologiesA
CareDx logo
CareDxCDNA

Other financials

Income statement

See full
Revenue$186.7M+11.1%
Gross profit$80.9M+10.4%
Operating income-$18.2M+34.4%
Net income-$17.1M+34.0%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$146.1M-57.8%
Total debt$66.3M+5.3%
Total equity$828.8M-6.7%
Total assets$1.3B-15.9%

Cash flow

See full
Operating cash flow-$8.1M+67.9%
CapEx$5.0M+11.1%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$1.68B-21.0%
Enterprise value$1.6B-5.6%
P/S2.3×-0.9×

Profitability

See full
Gross margin43.2%-1.1pp
Operating margin-14.2%+1.1pp
Net margin-13.3%+2.4pp
FCF margin-4.9%

Returns & leverage

See full
Return on equity-11.6%+6.2pp
Debt / equity0.1×0.0×
Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesOutstanding.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's common stock, shares, outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NeoGenomics's common stock, shares, outstanding?
NeoGenomics (NEO) reported common stock, shares, outstanding of $129.65M in Q1 2026.
How has NeoGenomics's common stock, shares, outstanding changed year-over-year?
NeoGenomics's common stock, shares, outstanding increased by 1.0% year-over-year, from $128.36M to $129.65M.